Stemgent recently raised $6.3 million, according to filings with the SEC. Stemgent plans for an $8.8 million top end for the round. The new equity round saw participation from eight backers.

Stemgent, Inc. is engaged in working alongside some of the world's leading stem cell scientists in developing innovative technology and application solutions for the advancement of stem cell research. The firm's mission is to help simplify and support cellular reprogramming research by producing products being designed by leading stem cell researchers worldwide. The firm's scientific development sites are located in both Cambridge, Massachusetts and San Diego, California.